Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS)
CNY 13.44
(-0.07%)
CNY 13.44
(-0.07%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.63 Billion | 595.44 Million | 683.63 Million | -565.84 Million | -841.38 Million | 62.36 Million |
| Net Income | -189.44 Million | 1.08 Billion | 1.06 Billion | 796.65 Million | 606.24 Million | 424.54 Million |
| Depreciation & Amortization | 154.24 Million | 139.53 Million | 93.22 Million | 84.54 Million | 44.98 Million | 39.86 Million |
| Deferred income taxes | -249.58 Million | -28.36 Million | -11.47 Million | -8.37 Million | -8.65 Million | -133.37 Thousand |
| Stock-based compensation | 42.85 Million | 28.36 Million | 8.97 Million | 8.38 Million | 1.37 Million | 1.34 Million |
| Change in working capital | 601.3 Million | -506.38 Million | -556.9 Million | -1.56 Billion | -1.5 Billion | -400.51 Million |
| Other non-cash items | 1.02 Billion | -122.77 Million | 85.89 Million | 118.52 Million | 17.21 Million | -1.53 Million |
| Investing Cash Flow | -1.17 Billion | -400.49 Million | 170.14 Million | -1.17 Billion | -153.61 Million | 204.25 Million |
| Investments in PPE | -419.06 Million | -470.07 Million | -440.75 Million | -294.36 Million | -115.4 Million | -82.76 Million |
| Acquisitions | 152.91 Thousand | 112.03 Thousand | -13.87 Million | 117.08 Thousand | -25.57 Million | 82.81 Million |
| Investment purchases | -2.33 Billion | -2 Billion | -3.14 Billion | -2.59 Billion | -1.74 Billion | -2.66 Billion |
| Sales/Maturities of investments | 1.57 Billion | 2.06 Billion | 3.77 Billion | 1.71 Billion | 1.73 Billion | 2.94 Billion |
| Other Investing Activities | -742.97 Million | 1.38 | 539.72 Thousand | 1.03 Million | 312.99 Thousand | -82.76 Million |
| Financing Cash Flow | 51.19 Million | -310.81 Million | -912.39 Million | 1.97 Billion | 951.38 Million | -55.81 Million |
| Debt repayment | -308.37 Million | -3.43 Billion | -2.68 Billion | -2.31 Billion | -1.01 Billion | -777.71 Million |
| Dividends payments | -185.91 Million | -186.58 Million | -140.4 Million | -215.57 Million | -82.9 Million | -73.1 Million |
| Common Stock Repurchased | -5.72 Million | -1.12 Million | -873.97 Thousand | -1.03 Million | -2.38 Million | -67.45 Thousand |
| Common Stock Issuance | - | 1.12 Million | 873.97 Thousand | 1.03 Million | 2.38 Million | - |
| Other Financing Activities | -62.55 Million | 3.35 Billion | 1.96 Billion | 4.54 Billion | 2.06 Billion | 794.99 Million |
| Accounts receivables | 163.36 Million | -1.45 Billion | -148.2 Million | -345.26 Million | -202.11 Million | -48.29 Million |
| Accounts payables | 224.65 Million | 1.7 Billion | 46.82 Million | 11.23 Million | -61.64 Million | 303.22 Million |
| Inventory | 213.28 Million | -731.56 Million | -444.05 Million | -1.22 Billion | -1.23 Billion | -655.3 Million |
| Other working capital | -21.25 Million | -28.36 Million | -11.47 Million | -8.37 Million | -8.65 Million | 254.78 Million |
| Cash at beginning of period | 1.38 Billion | 434.64 Million | 473.21 Million | 248.43 Million | 287.64 Million | 69.95 Million |
| Cash at end of period | 1.2 Billion | 302.67 Million | 434.64 Million | 473.21 Million | 248.43 Million | 287.64 Million |
| Capital Expenditure | -419.06 Million | -470.07 Million | -440.75 Million | -294.36 Million | -115.4 Million | -82.76 Million |
| Effect of forex changes on cash | 83.18 Million | -16.11 Million | 20.04 Million | -9.88 Million | 4.4 Million | 6.89 Million |
| Net cash flow / Change in cash | -178.7 Million | -131.97 Million | -38.56 Million | 224.77 Million | -39.2 Million | 217.69 Million |
| Free Cash Flow | 1.21 Billion | 125.36 Million | 242.87 Million | -860.21 Million | -956.78 Million | -20.39 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 200.76 Million | 227.82 Million | 177.19 Million | -1.02 Billion | -189.44 Million | 214.8 Million |
| Depreciation & Amortization | - | 37.72 Million | 37.72 Million | 44.83 Million | 154.24 Million | -64.47 Million |
| Deferred income taxes | - | 54.4 Million | - | - | -249.58 Million | -40.94 Million |
| Stock-based compensation | - | 423.03 Thousand | - | 42.85 Million | 42.85 Million | -1.53 Million |
| Change in working capital | - | 116.03 Million | - | 355.39 Million | 601.3 Million | 106.32 Million |
| Other non-cash items | 224.85 Million | 160.94 Million | 23.79 Million | 1.53 Billion | 1.02 Billion | 326.65 Million |
| Investing Cash Flow | -579 Million | -601.53 Million | -789.96 Million | -972.57 Million | -1.17 Billion | -164.85 Million |
| Investments in PPE | -152.88 Million | -221.64 Million | -49.55 Million | -225.86 Million | -419.06 Million | -107.54 Million |
| Acquisitions | - | - | - | -1.4 Million | 152.91 Thousand | 799.12 Thousand |
| Investment purchases | -1.57 Billion | -913.12 Million | -1.12 Billion | -834.67 Million | -2.33 Billion | -769.6 Million |
| Sales/Maturities of investments | 1.15 Billion | 548.9 Million | 382.01 Million | 89.37 Million | 1.57 Billion | 711.49 Million |
| Other Investing Activities | 641.28 Thousand | -15.67 Million | -740.41 Million | -733.32 Million | -742.97 Million | 0.68 |
| Financing Cash Flow | -69.18 Million | 234 Million | 481.8 Million | 717.4 Million | 51.19 Million | -367.54 Million |
| Debt repayment | -109.43 Million | -251.1 Million | -493.02 Million | -727.67 Million | -308.37 Million | -1 Billion |
| Dividends payments | -178.61 Million | -17.1 Million | -11.22 Million | -1.56 Million | -185.91 Million | -205.39 Million |
| Common Stock Repurchased | - | -11.93 Million | - | -5.72 Million | -5.72 Million | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -190.55 Million | -17.1 Million | -11.22 Million | 184.34 Million | -62.55 Million | 841.6 Million |
| Accounts receivables | - | -302.5 Million | - | 163.36 Million | 163.36 Million | 137.59 Million |
| Accounts payables | - | - | - | - | 224.65 Million | -40.4 Million |
| Inventory | - | 494.38 Million | - | 213.28 Million | 213.28 Million | -31.26 Million |
| Other working capital | - | -75.85 Million | - | -21.25 Million | -21.25 Million | 40.4 Million |
| Cash at beginning of period | 820.62 Million | 1.41 Billion | 1.2 Billion | 2.1 Billion | 1.38 Billion | 609.88 Million |
| Cash at end of period | 626.53 Million | 1.34 Billion | 1.41 Billion | 1.2 Billion | 1.2 Billion | 544.89 Million |
| Capital Expenditure | -152.88 Million | -221.64 Million | -49.55 Million | -225.86 Million | -419.06 Million | -107.54 Million |
| Effect of forex changes on cash | 5.46 Million | -4.07 Million | -236.64 Thousand | 143.1 Million | 83.18 Million | -73.43 Million |
| Net cash flow / Change in cash | -194.08 Million | -72.34 Million | 209.27 Million | -897.12 Million | -178.7 Million | -64.99 Million |
| Free Cash Flow | 272.74 Million | 183.8 Million | 151.43 Million | 235.49 Million | 1.21 Billion | 433.28 Million |
4GBL
HLZ
002277
AAB
NGIND
SURYODAY